Call
+918447748545

Published on: Apr 04, 2020
2 minute read
By: Dr Rajan Choudhary

THE CHALLENGES FACED IN MAKING A VACCINE FOR COVID-19 — Part 2

Previously we’ve seen the difficulties researches face in trying to make a vaccine. But even if we make a vaccine, that’s just half the battle. Viruses are unique because they can mutate, and they can mutate to astonishing degrees. In humans mutations to tiny parts of our DNA can cause severe diseases or even death. In viruses mutations can change their structure, making them more infective and giving them a new coat. It gives them a survival advantage, the ability to evade our immune system and make our vaccines ineffective. This is why we need a new flu vaccine every year.

If it takes months to a year to develop a vaccine, it will be based off the virus found in December 2019. By this time the virus may have spread and mutated to such a degree that it is not effective. This does not mean all the effort was for nothing. Going through the steps and understanding the issues faced with making a COVID-19 vaccine can make the process quicker for subsequent vaccines against its mutated versions.

https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away So Long to Develop a Vaccine

FAILURES FROM THE PAST

These issues were faced during the Ebola and Zika virus epidemics, and many large companies are understandably hesitant to develop vaccines for COVID-19. Ebola first broke out in 2014, and it was only in December 2019 that the first vaccine was approved for use by the European Commission and the United States. This is despite multiple large institutes in Canada and the UK working together to develop it.

13 different Ebola vaccine candidates had been identified soon after the outbreak, but none had been tested on humans. Unfortunately this is the most expensive part of development, and the area biopharmecuticals stand to loose the most money. Return on investments is also low, since epidemics usually take place in poorer countries, and the potential customers are unable to pay the high prices for these brand new treatments. It is an unfortunate realisation that research into medicines is driven by rich countries, for diseases that affect the rich.

https://newint.org/features/web-exclusive/2016/06/16/why-did-the-market-fail-to-produce-an-ebola-vaccine Ebola

WHERE ARE WE NOW?

This is all well and good, but what does it mean for COVID-19? We know we cannot rush a vaccine, because a poorly designed vaccine with unknown side effects can cause more harm than good, especially if given to children or the elderly. Currently the WHO are tracking 31 different attempts at making a COVID-19 vaccine, using different methods as discussed before. All of these are currently in the pre-clinical stage, focusing on isolating parts of the virus and creating a target the body will recognise and react to.

Researchers at the University of Queensland were one of the first to start using the genetic code of COVID-19, released openly by Chinese researchers. They have developed a test vaccine within 6 weeks using state-of-the-art genetic techniques, used for the first time. If animal models prove successful then human testing might begin within 6 months. In the pharmaceutical industry advancements this quick are almost unheard of.

Additionally over 293 clinical trials are taking place in China using existing drugs on the market. The advantage is we already know these drugs are safe to use in humans, but we are trying to work out if they will work against COVID-19. Some scientists are also looking at medications that were initially developed against SARS and MERS, but never completed because these outbreaks died down and the medication was no longer required.

https://www.aljazeera.com/news/2020/03/china-recovered-develop-effective-covid-19-treatments-200302082850237.html COVID-19 treatments

https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1 WHO news

https://www.theverge.com/2020/2/28/21156385/covid-coronavirus-vaccine-treatment-moderna-remdesivir-research COVID-19 treatment

Its not all doom and gloom. Challenges drive innovation, and we are already benefitting from this. New forms of genetic sequencing, new methods for extracting viral proteins, new techniques in creating a vaccine. These innovations are already benefitting us on the drive to create an effective vaccine for COVID-19, and they will benefit us in the future when the next pandemic hits.

Dr Rajan Choudhary, Product Manager Second Medic UK

www.secondmedic.com

Read Blog

Monkeypox Virus Symptoms: Early Signs, Disease Progression, and When to Seek Care

Monkeypox, now commonly referred to as mpox, is a viral infection that has gained global attention due to outbreaks beyond traditionally affected regions. Understanding monkeypox virus symptoms is essential for early detection, timely isolation and prevention of further spread.

According to the World Health Organization and Indian public health authorities, awareness of symptom patterns plays a critical role in controlling outbreaks and protecting vulnerable populations.

What Is the Monkeypox Virus?

Monkeypox is caused by the monkeypox virus, a member of the Orthopoxvirus family, which also includes smallpox. While generally less severe than smallpox, monkeypox can still cause significant illness and discomfort.

The virus spreads primarily through close physical contact.

Incubation Period of Monkeypox

After exposure, symptoms typically appear within:

5 to 21 days
most commonly 6 to 13 days

Individuals may feel well during this period but can become infectious once symptoms begin.

Early Monkeypox Virus Symptoms

Fever

Fever is usually the first symptom and may be:

sudden in onset
moderate to high grade
accompanied by chills

Fever signals the start of systemic infection.

Headache and Body Aches

Patients often experience:

severe headache
muscle aches
back pain

These symptoms resemble many viral illnesses.

Fatigue and Weakness

Marked tiredness and low energy levels are common and may limit daily activities.

Swollen Lymph Nodes

Swollen lymph nodes are a distinguishing feature of monkeypox.

Common sites include:

neck
armpits
groin

This helps differentiate monkeypox from chickenpox or smallpox.

Development of Monkeypox Rash

The skin rash usually appears:

1 to 3 days after fever onset

It may begin on the face or genital area and spread to other parts of the body.

Stages of Monkeypox Rash

The rash progresses through well-defined stages:

Macules

Flat red spots on the skin.

Papules

Raised, firm bumps.

Vesicles

Fluid-filled blisters.

Pustules

Pus-filled lesions that are painful.

Scabs

Lesions crust over and eventually fall off.

Complete healing occurs once scabs detach.

Distribution of Rash

Rash commonly affects:

face
hands and feet
mouth
genital and anal areas

The number of lesions can vary widely.

Pain and Discomfort

Rash lesions may be:

painful
itchy during healing

Pain severity differs between individuals.

Other Possible Symptoms

Additional symptoms may include:

sore throat
cough
nasal congestion

These reflect upper respiratory involvement.

Duration of Illness

Monkeypox symptoms typically last:

2 to 4 weeks

Recovery occurs gradually as lesions heal.

Who Is at Higher Risk of Severe Illness?

Higher risk groups include:

children
pregnant women
individuals with weakened immunity
people with chronic illness

Early care is crucial in these groups.

Complications of Monkeypox

Though uncommon, complications may include:

secondary bacterial skin infections
dehydration
pneumonia
eye involvement

Prompt medical guidance reduces risk.

How Monkeypox Is Transmitted

Transmission occurs through:

direct skin-to-skin contact
contact with lesions or bodily fluids
respiratory droplets during close contact
contaminated clothing or bedding

Understanding transmission helps prevent spread.

When to Seek Medical Care

Seek medical evaluation if:

fever is followed by rash
lymph nodes become swollen
rash appears in genital or facial areas

Early diagnosis supports isolation and care.

Diagnosis and Testing

Diagnosis may involve:

clinical examination
laboratory testing of lesion samples

Public health authorities guide testing protocols.

Prevention and Control Measures

Preventive steps include:

avoiding close contact with infected individuals
maintaining good hand hygiene
isolating during illness
following public health guidance

Vaccination may be recommended for high-risk groups.

Role of Public Awareness

Awareness of symptoms:

enables early detection
reduces stigma
supports timely care

WHO emphasises community education in outbreak control.

Conclusion

Monkeypox virus symptoms typically begin with fever, body aches and swollen lymph nodes, followed by a characteristic rash that progresses through defined stages. While most cases are self-limiting, early recognition, medical evaluation and isolation are essential to prevent complications and reduce transmission. Staying informed and acting promptly protects both individual and public health.

References

World Health Organization (WHO) – Mpox (Monkeypox) Clinical and Public Health Guidance
Indian Council of Medical Research (ICMR) – Emerging Viral Infections Reports
National Centre for Disease Control (NCDC), India – Monkeypox Advisories
Lancet – Clinical Features and Outcomes of Mpox
NITI Aayog – Public Health Preparedness and Infectious Disease Control

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.